| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| Other Sizes |
|
Purity: ≥98%
| Targets |
ERK1; ERK2; Autophagy
|
|---|---|
| ln Vitro |
Honokiol exhibits pro-apoptotic effects in melanoma, sarcoma, myeloma, leukemia, bladder, lung, prostate, oral squamous cell carcinoma, and colon cancer cell lines. Honokiol is effective at causing apoptosis in SVR angiosarcoma cells. When honokiol is used to treat SVR cells, less MAP kinase, akt, and c-src are phosphorylated. Additionally, TRAIL-mediated apoptosis is potentiated by honokiol, and the cytotoxicity of honokiol is partially reversed by TRAIL-neutralizing antibodies. Honokiol also has direct antiangiogenic properties, as it prevents phosphorylation and rac activation brought on by VEGF-VEGFR2 interactions.[1] Honokiol activates caspase 8, which is followed by caspase 9, and then it activates caspase 3 to cause apoptosis in CLL cells. Honokiol inhibits the interleukin-4-mediated survival of CLL cells and increases the cytotoxicity of chlorambucil, fludarabine, and cladribine. [3] Honokiol kills myeloma cells from relapsed patients at doses that do not kill PBMCs. Treatment with honokiol and PARP cleavage both induce caspases 3, 7, 8, and 9.[2] Honokiol has been found to cause apoptosis in the colon cancer cell lines RKO. [4] By modifying the nuclear factor-kappaB activation pathway, honokiol promotes apoptosis, inhibits osteoclastogenesis, and prevents invasion. Honokiol has an inhibitory effect on the PI3K/Akt pathway, which may make it a potent anti-inflammatory drug with a variety of potential uses.[6]
|
| ln Vivo |
Honokiol is very successful in treating SVR angiosarcoma in naked mice. [1] In murine xenografts, honokiol prevents the growth of RKO cells. [4] In murine xenografts, honokiol inhibits the growth of MDA-MD-231 breast cancer cells. [7]
|
| Cell Assay |
In cytotoxicity tests, 96-well plates with 10,000 cells per well are added and allowed to stand overnight before the cells are exposed to various Honokiol concentrations dissolved in DMSO. For in vitro studies, honokiol is dissolved in DMSO because it is not soluble in aqueous solvents. Solvent (DMSO) control is used at a maximum concentration of <0.1% to investigate the potential impact of DMSO on cells. Cells are fixed 72 hours after treatment, and crystal violet staining (0.05%) is used to assess cell viability.
|
| Animal Protocol |
The MDA-MB-231 cells (2 million) are injected into mammary fat tissue for anticancer in vivo studies. Palpable tumors are seen in mammary tissues two weeks after the tumor cell injections, which is a sign that a tumor has formed. The medication is then administered orally at doses of 40 and 80 mg/kg per day, either in free form or in nanomicellar form. The drug treatment is continued for another four weeks, and weekly weight and tumor volume measurements are made. Animals are sacrificed after 4 weeks of treatment, and the final tumor weights and volumes are assessed. For immunohistochemical and western blot analyses, these tumors are used.
|
| References |
[1]. J Biol Chem . 2003 Sep 12;278(37):35501-7. [2]. Blood . 2005 Sep 1;106(5):1794-800. [3]. Blood . 2005 Jul 15;106(2):690-7. [4]. World J Gastroenterol . 2004 Aug 1;10(15):2205-8. [5]. https://pubmed.ncbi.nlm.nih.gov/16966432/ [6]. Acta Pharmacol Sin . 2008 Jan;29(1):113-22. |
| Molecular Formula |
C18H18O2
|
|
|---|---|---|
| Molecular Weight |
266.334
|
|
| Exact Mass |
266.13
|
|
| Elemental Analysis |
C, 81.17; H, 6.81; O, 12.01
|
|
| CAS # |
35354-74-6
|
|
| Related CAS # |
|
|
| Appearance |
solid powder
|
|
| SMILES |
C=CCC1=CC(=C(C=C1)O)C2=CC(=C(C=C2)O)CC=C
|
|
| InChi Key |
FVYXIJYOAGAUQK-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C18H18O2/c1-3-5-13-7-9-18(20)16(11-13)14-8-10-17(19)15(12-14)6-4-2/h3-4,7-12,19-20H,1-2,5-6H2
|
|
| Chemical Name |
2-(4-hydroxy-3-prop-2-enylphenyl)-4-prop-2-enylphenol
|
|
| Synonyms |
Honokiol, Houpa; Hnk
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.39 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.39 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.39 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 2% DMSO+40% PEG 300+2% Tween 80+ddH2O: 2mg/mL Solubility in Formulation 5: 16.67 mg/mL (62.59 mM) in Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7547 mL | 18.7737 mL | 37.5474 mL | |
| 5 mM | 0.7509 mL | 3.7547 mL | 7.5095 mL | |
| 10 mM | 0.3755 mL | 1.8774 mL | 3.7547 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00966953 | Completed | Drug: Triclosan/Fluoride toothpaste Drug: Fluoride |
Gingival Diseases | Colgate Palmolive | October 2007 | Phase 3 |
|
honokiol inhibits phosphorylation of AKT, p44/42 MAPK, and Src. |
Effect of honokiol on in vivo growth of SVR angiosarcoma in nude mice. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
Effect of honokiol and magnolol on apoptosis. J Biol Chem, 2003, 278(37), 35501-35507.
